Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-MAP2K1IP1 antibody [Y130] (ab32134)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [Y130] to MAP2K1IP1
  • Suitable for: WB, IHC-P, ICC/IF
  • Knockout validated
  • Reacts with: Human

Overview

  • Product name

    Anti-MAP2K1IP1 antibody [Y130]
    See all MAP2K1IP1 primary antibodies

  • Description

    Rabbit monoclonal [Y130] to MAP2K1IP1

  • Host species

    Rabbit

  • Specificity

    ab32134 recognises MP1 (MEK partner-1).

  • Tested Applications & Species

    Application Species
    ICC/IF
    Human
    IHC-P
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    A synthetic peptide corresponding to residues in the C-terminus of human mitogen activated protein kinase kinase 1 interacting protein 1

  • Positive control

    • WB: HeLa and A431 cell lysates. IHC-P: Human breast carcinoma tissue. ICC/IF: MCF7 cells.

  • General notes

    Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

  • Form

    Liquid

  • Storage instructions

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

  • Storage buffer

    pH: 7.20
    Preservative: 0.01% Sodium azide
    Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA
  • Concentration information loading...

  • Purity

    Protein A purified

  • Clonality

    Monoclonal

  • Clone number

    Y130

  • Isotype

    IgG

  • Research areas

Images

  • Western blot - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Western blot - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    All lanes : Anti-MAP2K1IP1 antibody [Y130] (ab32134) at 1/50000 dilution

    Lane 1 : Wild-type HeLa cell lysate
    Lane 2 : MAP2K1IP1 knockout HeLa cell lysate

    Lysates/proteins at 20 µg per lane.

    Performed under reducing conditions.


    Lanes 1-2: Merged signal (red and green). Green - ab32134 observed at 14 kDa. Red - loading control ab8245 observed at 37 kDa.

     ab32134 Anti-MAP2K1IP1 antibody [Y130] was shown to specifically react with MAP2K1IP1 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265624 (knockout cell lysate ab258021) was used. Wild-type and MAP2K1IP1 knockout samples were subjected to SDS-PAGE. ab32134 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 50000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

     

  • Western blot - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Western blot - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Anti-MAP2K1IP1 antibody [Y130] (ab32134) at 1/50000 dilution + A431 cell lysate

    Observed band size: 14 kDa
    why is the actual band size different from the predicted?

  • Immunocytochemistry/ Immunofluorescence - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Immunocytochemistry/ Immunofluorescence - Anti-MAP2K1IP1 antibody [Y130] (ab32134)

    Immunocytochemistry/ Immunofluorescence analysis of MCF7 (human breast adenocarcinoma epithelial cell) cells labeling MAP2K1IP1 with purified ab32134 at 1/100 dilution (10 µg/mL). Cells were fixed in 100% Methanol and permeabilized with None. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/mL) dilution. DAPI (blue) was used as nuclear counterstain. ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/mL) was used as the secondary antibody only control.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MAP2K1IP1 antibody [Y130] (ab32134)

    ab32134, staining human breast carcinoma by immunohistochemistry, Paraffin embedded tissue

    Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MAP2K1IP1 antibody [Y130] (ab32134)

    ab32134 showing positive staining in Breast carcinoma tissue.

    Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

  • Anti-MAP2K1IP1 antibody [Y130] (ab32134)
    Anti-MAP2K1IP1 antibody [Y130] (ab32134)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-MAP2K1IP1 antibody [Y130] (ab32134)

© 2021 Astana Biomed Group LLP. All rights reserved.